Selected article for: "acute respiratory syndrome and adjuvant formulation"
Author: McPherson, Clifton; Chubet, Richard; Holtz, Kathy; Honda-Okubo, Yoshikazu; Barnard, Dale; Cox, Manon; Petrovsky, Nikolai
Title: Development of a SARS Coronavirus Vaccine from Recombinant Spike Protein Plus Delta Inulin Adjuvant
  • Cord-id: ibac3d0q
  • Document date: 2015_12_17
    • ID: ibac3d0q
    Snippet: Given periodic outbreaks of fatal human infections caused by coronaviruses, development of an optimal coronavirus vaccine platform capable of rapid production is an ongoing priority. This chapter describes the use of an insect cell expression system for rapid production of a recombinant vaccine against severe acute respiratory syndrome coronavirus (SARS). Detailed methods are presented for expression, purification, and release testing of SARS recombinant spike protein antigen, followed by adjuva
    Document: Given periodic outbreaks of fatal human infections caused by coronaviruses, development of an optimal coronavirus vaccine platform capable of rapid production is an ongoing priority. This chapter describes the use of an insect cell expression system for rapid production of a recombinant vaccine against severe acute respiratory syndrome coronavirus (SARS). Detailed methods are presented for expression, purification, and release testing of SARS recombinant spike protein antigen, followed by adjuvant formulation and animal testing. The methods herein described for rapid development of a highly protective SARS vaccine are equally suited to rapid development of vaccines against other fatal human coronavirus infections, e.g., the MERS coronavirus.

    Search related documents:
    Co phrase search for related documents
    • acute sars respiratory syndrome coronavirus and adjuvant advax: 1
    • acute sars respiratory syndrome coronavirus and adjuvant formulation: 1
    • acute sars respiratory syndrome coronavirus and live virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute sars respiratory syndrome coronavirus and low immunogenicity: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute sars respiratory syndrome coronavirus and lung clearance: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • acute sars respiratory syndrome coronavirus and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute sars respiratory syndrome coronavirus and lung distribution: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • acute sars respiratory syndrome coronavirus and lung distribution parenchyma: 1
    • adjuvant advax and live virus: 1
    • adjuvant advax and low immunogenicity: 1
    • adjuvant formulation and live virus: 1
    • adjuvant formulation and low immunogenicity: 1
    • live virus and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9